Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACADNASDAQ:AGIONASDAQ:APLSNASDAQ:NKTRNASDAQ:TPTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$16.71+2.5%$20.11$16.16▼$33.99$2.75B0.371.76 million shs1.17 million shsAGIOAgios Pharmaceuticals$31.49-0.6%$30.01$19.80▼$35.50$1.77B0.83803,388 shs417,224 shsAPLSApellis Pharmaceuticals$49.86+4.0%$58.21$19.83▼$94.75$6.01B0.881.48 million shs980,419 shsNKTRNektar Therapeutics$1.32$1.03$0.41▼$1.75$242.38M0.92.13 million shs559,088 shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals+2.45%-0.65%-8.19%-37.97%-17.73%AGIOAgios Pharmaceuticals-0.57%+6.64%+8.14%+34.69%+42.49%APLSApellis Pharmaceuticals+4.03%+4.90%-14.75%-22.14%-41.12%NKTRNektar Therapeutics0.00%+6.45%+49.14%+159.33%+64.88%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACADACADIA Pharmaceuticals3.8653 of 5 stars4.42.00.00.01.14.21.9AGIOAgios Pharmaceuticals1.0768 of 5 stars1.31.00.04.71.10.80.0APLSApellis Pharmaceuticals4.5011 of 5 stars4.41.00.04.43.12.50.6NKTRNektar Therapeutics3.7317 of 5 stars3.03.00.04.21.02.50.6TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals2.80Moderate Buy$35.82114.38% UpsideAGIOAgios Pharmaceuticals2.50Moderate Buy$33.506.38% UpsideAPLSApellis Pharmaceuticals2.87Moderate Buy$77.9356.30% UpsideNKTRNektar Therapeutics2.00Hold$3.50165.15% UpsideTPTXTurning Point TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest NKTR, ACAD, TPTX, AGIO, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/26/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.004/25/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.004/17/2024APLSApellis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$67.00 ➝ $57.004/15/2024APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$92.004/10/2024ACADACADIA PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$37.004/9/2024ACADACADIA PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.004/9/2024AGIOAgios PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight4/9/2024APLSApellis PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$85.003/27/2024APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$60.003/25/2024ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$29.00 ➝ $25.003/13/2024ACADACADIA PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $30.00(Data available from 4/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$726.44M3.79N/AN/A$2.63 per share6.35AGIOAgios Pharmaceuticals$26.82M65.97N/AN/A$14.51 per share2.17APLSApellis Pharmaceuticals$396.59M15.16N/AN/A$1.64 per share30.40NKTRNektar Therapeutics$90.12M2.69N/AN/A$0.69 per share1.91TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals-$61.29M-$0.38N/A14.28N/A-8.44%-15.67%-9.15%5/8/2024 (Confirmed)AGIOAgios Pharmaceuticals-$352.09M-$6.34N/AN/AN/A-1,312.64%-38.08%-33.69%5/2/2024 (Confirmed)APLSApellis Pharmaceuticals-$528.63M-$4.48N/A46.17N/A-133.34%-178.60%-60.41%5/7/2024 (Confirmed)NKTRNektar Therapeutics-$276.06M-$1.46N/AN/AN/A-306.31%-96.80%-37.17%5/14/2024 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest NKTR, ACAD, TPTX, AGIO, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AACADACADIA Pharmaceuticals$0.17N/A-$0.17N/AN/AN/A 5/7/2024N/AAPLSApellis Pharmaceuticals-$0.55N/A+$0.55N/AN/AN/A 5/2/2024N/AAGIOAgios Pharmaceuticals-$1.63N/A+$1.63N/AN/AN/A 3/4/202412/31/2023NKTRNektar Therapeutics-$0.21-$0.22-$0.01-$0.22$17.09 million$23.89 million 2/27/2024Q4 2023ACADACADIA Pharmaceuticals$0.32$0.28-$0.04$0.28$223.79 million$231.04 million 2/27/202412/31/2023APLSApellis Pharmaceuticals-$0.73-$0.73N/A-$0.73$143.34 million$146.38 million 2/15/2024Q4 2023AGIOAgios Pharmaceuticals-$1.64-$1.72-$0.08-$1.72$7.80 million$7.10 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.422.28AGIOAgios PharmaceuticalsN/A12.2711.99APLSApellis Pharmaceuticals0.483.102.50NKTRNektar TherapeuticsN/A6.456.14TPTXTurning Point TherapeuticsN/A16.8316.83OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%AGIOAgios PharmaceuticalsN/AAPLSApellis Pharmaceuticals96.29%NKTRNektar Therapeutics75.88%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals27.50%AGIOAgios Pharmaceuticals4.24%APLSApellis Pharmaceuticals7.50%NKTRNektar Therapeutics3.07%TPTXTurning Point Therapeutics8.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals597164.77 million119.46 millionOptionableAGIOAgios Pharmaceuticals38356.19 million53.81 millionOptionableAPLSApellis Pharmaceuticals702120.58 million111.54 millionOptionableNKTRNektar Therapeutics137183.62 million177.98 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableNKTR, ACAD, TPTX, AGIO, and APLS HeadlinesSourceHeadlineGlass System in Turning Point Residencearchdaily.com - April 2 at 10:51 AMBid to remove prosecutors sets up turning point in Trump’s Georgia casepolitico.com - February 19 at 11:51 PMTurning Point Brands Inc.wsj.com - February 17 at 11:42 PMAlzheimer’s: A Turning Point?bbc.co.uk - February 12 at 4:29 PMTurning Point Brands Inc (TPB)investing.com - February 10 at 7:36 PMCormorant Asset Management, LP's Net Worthbenzinga.com - February 10 at 7:36 PMSolving quadratic equations - Edexcelbbc.co.uk - January 15 at 9:15 AMCOP15: A Turning Point for Investor Approaches to Biodiversitymorningstar.com - December 19 at 12:52 PMTurning Point USA: Are conservatives fighting back on campus?bbc.com - December 16 at 3:14 PMBMS bet looking good as Augtyro approved in ROS1-positive NSCLCthepharmaletter.com - November 16 at 12:30 PMPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodulster.ac.uk - October 29 at 7:58 PMA Turning Point for Japan-US Climate Cooperation?thediplomat.com - October 28 at 1:00 PMWhat to know about the Turning Point USA incident on Arizona State University's campusazcentral.com - October 28 at 1:00 PMRight-wingers start to turn on this pro-Trump propaganda groupmsnbc.com - October 28 at 1:00 PMUAW, Detroit Three careen toward another Friday turning pointautoblog.com - October 16 at 6:04 PMTrump's youth whisperers living large as MAGA candidates failmsnbc.com - October 14 at 1:16 PMSong Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...Song Hye-Kyo Calls ‘The Glory’ A Turning Point Of Her Career...koimoi.com - October 5 at 8:10 AMThe revised economic figures are a huge lucky break for Sunak – and could be a turning pointindependent.co.uk - September 17 at 4:14 PMDespite previous campus firestorm, Turning Point USA to welcome conservative speakers at ASUazcentral.com - September 15 at 12:34 AMThis law may be the turning point in America’s fight to save the planetmsnbc.com - August 21 at 7:44 AMTattoos have reached a turning point at workft.com - July 29 at 11:36 PMTurning Point’s #ACTCON was a pro-Trump lovefest designed to intimidatemsnbc.com - July 25 at 10:25 AM‘Turning point’ in the fight against Alzheimer’s as drug found to slow diseaseindependent.co.uk - July 23 at 3:37 PMMargaret Thatcher, a turning point in British politicsen.mercopress.com - July 19 at 12:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsACADIA PharmaceuticalsNASDAQ:ACADACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Agios PharmaceuticalsNASDAQ:AGIOAgios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Apellis PharmaceuticalsNASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Nektar TherapeuticsNASDAQ:NKTRNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Turning Point TherapeuticsNASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.